Hims & Hers
Coverage of Hims & Hers in the Nexus archive.
- STAT+: Online care is caught in the crossfire as states crack down on corporate medicine
Telehealth companies like Hims & Hers and Teladoc have grown into a multi-billion-dollar industry, but face legal challenges in over 30 states where corporations are prohibited from practicing medicine. To comply, these companies partner with independent medical groups owned by physicians who hold multiple state licenses, ensuring clinical decisions prioritize patient needs over corporate profits.
- Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance
Hims & Hers' stock plummets 15% after reporting a first-quarter loss and weak earnings guidance. The company had previously reached a deal with Novo Nordisk to sell the GLP-1 weight loss drug Wegovy on its platform. This partnership was announced in March.
- RFK Jr.'s peptide push could become next wellness boom
RFK Jr. advocates for loosening federal restrictions on peptides, potentially boosting telehealth companies, compounding pharmacies, and longevity clinics. The FDA will review peptide regulations in July, while experts debate their efficacy and safety, with market projections reaching $180 billion in five years.